47 related articles for article (PubMed ID: 19579280)
1. Cetuximab for metastatic colorectal cancer.
Bria E; Cuppone F; Di Maio M
N Engl J Med; 2009 Jul; 361(1):95-6; author reply 96-7. PubMed ID: 19579280
[No Abstract] [Full Text] [Related]
2. Cetuximab for metastatic colorectal cancer.
Roila F; Garassino MC; Ballatori E
N Engl J Med; 2009 Jul; 361(1):95; author reply 96-7. PubMed ID: 19579279
[No Abstract] [Full Text] [Related]
3. BRAF mutation in metastatic colorectal cancer.
Tol J; Nagtegaal ID; Punt CJ
N Engl J Med; 2009 Jul; 361(1):98-9. PubMed ID: 19571295
[No Abstract] [Full Text] [Related]
4. Cetuximab for metastatic colorectal cancer.
Garattini S; Torri V; Floriani I
N Engl J Med; 2009 Jul; 361(1):96; author reply 96-7. PubMed ID: 19579281
[No Abstract] [Full Text] [Related]
5. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy.
Di Fiore F; Blanchard F; Charbonnier F; Le Pessot F; Lamy A; Galais MP; Bastit L; Killian A; Sesboüé R; Tuech JJ; Queuniet AM; Paillot B; Sabourin JC; Michot F; Michel P; Frebourg T
Br J Cancer; 2007 Apr; 96(8):1166-9. PubMed ID: 17375050
[TBL] [Abstract][Full Text] [Related]
6. Toll-like receptor 9 agonist IMO cooperates with cetuximab in K-ras mutant colorectal and pancreatic cancers.
Rosa R; Melisi D; Damiano V; Bianco R; Garofalo S; Gelardi T; Agrawal S; Di Nicolantonio F; Scarpa A; Bardelli A; Tortora G
Clin Cancer Res; 2011 Oct; 17(20):6531-41. PubMed ID: 21890455
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting.
Asseburg C; Frank M; Köhne CH; Hartmann JT; Griebsch I; Mohr A; Osowski U; Schulten J; Mittendorf T
Clin Ther; 2011 Apr; 33(4):482-97. PubMed ID: 21635994
[TBL] [Abstract][Full Text] [Related]
8. Cetuximab for metastatic colorectal cancer.
Spiro H
N Engl J Med; 2009 Jul; 361(1):95; author reply 96-7. PubMed ID: 19571293
[No Abstract] [Full Text] [Related]
9. K-ras mutations and cetuximab in colorectal cancer.
Codacci-Pisanelli G; Spinelli G; Tomao S
N Engl J Med; 2009 Feb; 360(8):835; author reply 835-6. PubMed ID: 19238679
[No Abstract] [Full Text] [Related]
10. K-ras mutations and benefit from cetuximab in advanced colorectal cancer.
Karapetis CS; Khambata-Ford S; Jonker DJ; O'Callaghan CJ; Tu D; Tebbutt NC; Simes RJ; Chalchal H; Shapiro JD; Robitaille S; Price TJ; Shepherd L; Au HJ; Langer C; Moore MJ; Zalcberg JR
N Engl J Med; 2008 Oct; 359(17):1757-65. PubMed ID: 18946061
[TBL] [Abstract][Full Text] [Related]
11. Cetuximab in the treatment of colorectal cancer.
Goldberg RM; Venook AP; Schilsky RL
Clin Adv Hematol Oncol; 2004 Nov; 2(11):1-10; quiz 11-12. PubMed ID: 16170891
[No Abstract] [Full Text] [Related]
12. K-ras mutations and cetuximab in colorectal cancer.
De Roock W; Lambrechts D; Tejpar S
N Engl J Med; 2009 Feb; 360(8):834; author reply 835-6. PubMed ID: 19238676
[No Abstract] [Full Text] [Related]
13. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab.
Khambata-Ford S; Garrett CR; Meropol NJ; Basik M; Harbison CT; Wu S; Wong TW; Huang X; Takimoto CH; Godwin AK; Tan BR; Krishnamurthi SS; Burris HA; Poplin EA; Hidalgo M; Baselga J; Clark EA; Mauro DJ
J Clin Oncol; 2007 Aug; 25(22):3230-7. PubMed ID: 17664471
[TBL] [Abstract][Full Text] [Related]
14. Bevacizumab in colorectal cancer.
Sonpavde G
N Engl J Med; 2004 Oct; 351(16):1690-1; author reply 1690-1. PubMed ID: 15483292
[No Abstract] [Full Text] [Related]
15. Trichomegaly and poliosis of the eyelashes during cetuximab treatment of metastatic colorectal cancer.
Rodriguez NA; Ascaso FJ
J Clin Oncol; 2011 Jun; 29(18):e532-3. PubMed ID: 21483009
[No Abstract] [Full Text] [Related]
16. Progression-free survival in bevacizumab-based first-line treatment for patients with metastatic colorectal cancer: is it a really good end point?
Montagnani F; Migali C; Fiorentini G
J Clin Oncol; 2009 Oct; 27(28):e132-3; author reply e134-5. PubMed ID: 19720898
[No Abstract] [Full Text] [Related]
17. Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab.
Lurje G; Nagashima F; Zhang W; Yang D; Chang HM; Gordon MA; El-Khoueiry A; Husain H; Wilson PM; Ladner RD; Mauro DJ; Langer C; Rowinsky EK; Lenz HJ
Clin Cancer Res; 2008 Dec; 14(23):7884-95. PubMed ID: 19047118
[TBL] [Abstract][Full Text] [Related]
18. Role of cetuximab and sorafenib in treatment of metastatic colorectal cancer.
Galal KM; Khaled Z; Mourad AM
Indian J Cancer; 2011; 48(1):47-54. PubMed ID: 21248446
[TBL] [Abstract][Full Text] [Related]
19. [Pharmacoeconomics of molecular target drug: K-ras testing and cetuximab for colorectal cancer as an example].
Shiroiwa T; Tsutani K
Nihon Rinsho; 2012 Nov; 70 Suppl 8():664-8. PubMed ID: 23513919
[No Abstract] [Full Text] [Related]
20. Drug combo beneficial in colorectal cancer.
Cancer Discov; 2015 Feb; 5(2):102. PubMed ID: 25656881
[No Abstract] [Full Text] [Related]
[Next] [New Search]
